6) Maintaining an appropriate phosphorus level is accomplished through dietary phosphate restriction, the use of phosphate binders
, and, in dialyzed patients, dialytic removal of phosphate.
The medications evaluated were vitamin D analogs (paricalcitol and calcitriol), phosphate binders
(calcium acetate and sevelamer), and a calcium-sensing receptor sensitizer (cinacalcet).
Education regarding the importance of phosphate binders
and compliance with medication was provided by dialysis nurses and patient participation was tracked on a "Tally board" within each unit.
The phenolic urethane, new urethane, furan, phenolic, alkyd oil and inorganic phosphate binders
at one pass have been successfully reclaimed at high levels (90%).
Lanthanum carbonate (Fosrenol[R]) is a non-aluminum, non-calcium phosphate binder
that first gained approval from Health Canada in 2006 for the treatment of hyperphosphatemia in dialysis patients (Health Canada, 2007).
Dietary restriction is absolutely necessary because of the limited binding capacity of the phosphate binders
At the same time, the increased dialysis length was associated with better control of hyperphosphatemia and prevention of secondary hyperparathyreoidism, along with reduced frequency of administration of phosphate binders
and metabolite of vitamin D [10-13].
Her elevated calcium x phosphorus product with very high serum parathyroid hormone levels further confirmed non-compliance with treatment, phosphate binders
, and diet (see Table 1).
Fermagate Tablets, which is a new phosphate binder
, has been shown to be safe and effective in treating hyperphosphatemia in phase 2 and 3 trials in CKD patients undergoing chronic haemodialysis.
Two studies (n=29) compared calcium carbonate with aluminium hydroxide as phosphate binder
New York, NY announced it has reached agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 clinical program for Zerenex (ferric citrate), its iron-based phosphate binder
for the treatment of elevated serum phosphorous levels (hyperphosphatemia), in patients with end stage renal disease (ESRD).
University, examined the interaction of levothyroxine with two relatively new drugs--colesevelam (Welchol), the newest bile acid sequestrant approved for hyperlipidemia and diabetes; and lanthanum carbonate (Fosrenol), a new phosphate binder
used in end-stage renal disease.